Original Article on Vanderbilt University Website
Vanderbilt University Medical Center is taking its clinical research tool to the commercial market via a startup that wants to help health care and pharmaceutical companies navigate the research and clinical trial process.
Vanderbilt’s Research Electronic Data Capture, or REDCap, will be available to third parties through a commercial licensing agreement it’s offering through nPhase, a startup in Encinitas, Calif. REDcap was created in 2004 by Paul Harris, director of the Vanderbilt Office of Research Informatics.
REDCap supports clinical and translational research and is accessible to not-for-profits under a no-cost license. Institutions around the globe, including many medical research groups as well as an art museum and a fishery, use the software for secure and confidential data management. There are about 300,000 researchers in 96 countries using the tool in more than 200,000 projects, according to VUMC.
“I’ve never worked with a study yet that didn’t need good solid data management,” Harris said.
The new commercial product, REDCap Cloud, will be cloud-based and designed for companies that want to commercialize products, said Vic Gatto, whose company, Selous Venture Society, led the angel investment in nPhase.
“When you need to commercialize the research, which is mostly done in pharmaceuticals and in health care, that’s when you need REDCap Cloud,” Gatto said.
The original REDCap will still be available through VUMC to not-for-profits. Harris expects there to be some connectivity between nPhase’s commercial product and the research tool so each can benefit from new features.
“One of the things I’ve seen in REDCap, if you give smart people good, solid tools, they will figure out new ways to use them,” said Harris, who describes it as a “Swiss Army knife” for researchers involved in studies.
Gatto said nPhase is talking with some potential early clients and expects to have customers in place soon.
REDCap Cloud is being developed by Vanderbilt and other research institutions. It will be available as part of Software as a Service and will comply with federal regulations for use in industry and government clinical research trials.
NPhase is in the market to raise $2 million of equity, according to a January filing with the U.S. Securities and Exchange Commission. As of Jan. 5, it had raised $1.5 million.
Reach Holly Fletcher at 615-259-8287 or on Twitter @hollyfletcher.